Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | FLT4 | P35916 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27603260 | 0.84 | FLT1 (0.48) | LMNAFLT1FLT4KDRKMT2A | |
| SCHEMBL5066728 | 0.83 | LMNA (0.50) | LMNAFLT1FLT4KDRKMT2A | |
| SCHEMBL4805072 | 0.81 | NPC1 (0.51) | LMNAKMT2AALDH1A1HPGDKDM4E | |
| SCHEMBL17502664 | 0.76 | KDM4E (0.59) | LMNAKMT2AALDH1A1MEN1TDP1 | |
| SCHEMBL1484183 | 0.74 | ABL1 (0.64) | LMNAFLT1FLT4KDRKMT2A | |
| SCHEMBL4801974 | 0.73 | FLT1 (0.48) | LMNAFLT1FLT4KDRKMT2A | |
| SCHEMBL11070999 | 0.72 | LMNA (0.41) | LMNAKMT2AALDH1A1MEN1NR1I2 | |
| SCHEMBL13850168 | 0.72 | KDM4E (0.50) | LMNAKMT2AALDH1A1MEN1TDP1 | |
| SCHEMBL1546491 | 0.72 | MAPK1 (0.50) | KMT2AMEN1TDP1KDM4EGAA | |
| SCHEMBL4729820 | 0.72 | LMNA (0.61) | LMNAKMT2AALDH1A1MEN1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371739-B2 | Aryl fructose-1,6-bisphosphatase inhibitors | METABASIS THERAPEUTICS, INC. (US) | 2008-05-13 | — | — | US | disclosed |
| EP-1607401-A1 | Novel aryl fructose-1,6-Bisphosphatase inhibitors | Metabasis Therapeutics, Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050176684-A1 | Novel aryl fructose-1,6-bisphosphatase inhibitors | BOOKSER BRETT C (US) | 2005-08-11 | — | — | US | disclosed |
| US-6919322-B2 | Phenyl Phosphonate Fructose-1,6-Bisphosphatase Inhibitors | METABASIS THERAPEUTICS, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1265907-A2 | NOVEL ARYL FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS | Metabasis Therapeutics, Inc. (US) | 2002-12-18 | — | — | EP | disclosed |
| US-20020040014-A1 | Novel aryl fructose-1,6-Bisphosphatase inhibitors | METABASIS THERAPEUTICS, INC. | 2002-04-04 | — | — | US | disclosed |
| WO-2001066553-A2 | NOVEL ARYL FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS | METABASIS THERAPEUTICS, INC. (US) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040014-A1 | Novel aryl fructose-1,6-Bisphosphatase inhibitors | FBP1, SLC5A1, G6PC1 | LMNA 4671/4885FLT1 442/4885FLT4 1924/4885 |
| US-20050176684-A1 | Novel aryl fructose-1,6-bisphosphatase inhibitors | FBP1, G6PC1, SLC5A1 | LMNA 4677/4885FLT1 461/4885FLT4 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.